Literature DB >> 15367885

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.

Panayiotis Loukopoulos1, Kengo Kanetaka, Masaaki Takamura, Tatsuhiro Shibata, Michiie Sakamoto, Setsuo Hirohashi.   

Abstract

OBJECTIVE: To establish a series of clinically relevant orthotopic transplantation models of human pancreatic adenocarcinoma from both cell lines and primary tumors under uniform experimental conditions.
METHODS: Ten pancreatic cancer cell lines and 12 primary tumors were orthotopically transplanted in SCID mice. The cell lines and xenografts were characterized for K-ras, BRAF, p53, p16, and DPC4 aberrations employing direct sequencing, immunohistochemistry, and Western blotting.
RESULTS: All xenografts showed high intrapancreatic tumorigenicity and extensive local tumor growth, and each showed a unique behavioral and genetic profile. Tumor characteristics were retained during serial passaging. The cell line-derived xenografts represented the entire expected range of histologic differentiation. Although the overall metastatic rate was moderate to high, the metastatic pattern varied; 4 cell lines showed a high metastatic rate to the liver. The primary tumor-derived xenografts retained their similarity to the corresponding original donor tumors with regard to histologic presentation and biologic behavior. K-ras, p53, p16, and DPC4 aberrations were revealed in 80%, 70%, 50%, and 40% of cell lines and 100%, 33%, 75%, and 58% of primary tumor derived xenografts, respectively. No BRAF mutations were present. The metastatic behavior of the xenografts was significantly associated with the degree of histologic differentiation, number of genes altered, and p53 status.
CONCLUSIONS: The new models reflected the wide range of patho-biological features and genetic alterations that characterize human pancreatic cancer and may be used collectively or selectively as a markedly improved in vivo tool for preclinical and molecular studies of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367885     DOI: 10.1097/00006676-200410000-00004

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  71 in total

1.  Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.

Authors:  Michele L Scotti; William R Bamlet; Thomas C Smyrk; Alan P Fields; Nicole R Murray
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 2.  Examining the utility of patient-derived xenograft mouse models.

Authors:  Samuel Aparicio; Manuel Hidalgo; Andrew L Kung
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

Review 3.  Heralding a new paradigm in 3D tumor modeling.

Authors:  Eliza L S Fong; Daniel A Harrington; Mary C Farach-Carson; Hanry Yu
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

4.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick
Journal:  Nat Protoc       Date:  2009-10-29       Impact factor: 13.491

Review 5.  Mouse models of cancer-associated thrombosis.

Authors:  Yohei Hisada; Nigel Mackman
Journal:  Thromb Res       Date:  2017-12-29       Impact factor: 3.944

Review 6.  Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.

Authors:  Craig D Logsdon; Thiruvengadam Arumugam; Vijaya Ramachandran
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-09       Impact factor: 4.052

7.  Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.

Authors:  Ingun Heiene Tveteraas; Monica Aasrum; Ingvild Johnsen Brusevold; John Ødegård; Thoralf Christoffersen; Dagny Sandnes
Journal:  Tumour Biol       Date:  2015-09-19

Review 8.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

9.  Modeling pancreatic cancer with organoids.

Authors:  Lindsey A Baker; Hervé Tiriac; Hans Clevers; David A Tuveson
Journal:  Trends Cancer       Date:  2016-04

10.  A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Authors:  Eliza L S Fong; Xinhai Wan; Jun Yang; Micaela Morgado; Antonios G Mikos; Daniel A Harrington; Nora M Navone; Mary C Farach-Carson
Journal:  Biomaterials       Date:  2015-11-09       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.